A Phase 3 interventional study of Enlicitide and Ezetimibe in Hypercholesterolemia, sponsored by Merck Sharp & Dohme LLC. Completed at 35 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing enlicitide in Hypercholesterolemia — 1 open to participants now, 3 under way, 3 of them phase 3. enlicitide · Hypercholesterolemia.
Among the 10 studies testing enlicitide in Hypercholesterolemia, this one is the 6th largest by enrollment, is one of 2 that started in 2024, is one of 6 in phase 3, and was the 6th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 10 studies testing enlicitide in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in India
Ages 18+
By country, each count listing its studies:
enlicitide: first FDA approval 2026 (LIPFENDRA). What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2022; this study’s year is marked. 2 started in 2024.
This study's enrollment of 301 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 302 across the 10 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 1 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
29 studies in Hypercholesterolemia by Merck & Co., Inc: 1 open now, 3 under way, 3 of them phase 3. Of 26 finished, 16 (62%) have results posted.
Among the 29 studies in Hypercholesterolemia by Merck & Co., Inc, this one is the 20th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2024, is one of 17 in phase 3, and was the 25th registered.
Merck & Co., Inc’s Hypercholesterolemia studies by the year they started, since 2002.
1 of the studies testing enlicitide in Hypercholesterolemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07821944Phase 3Merck Sharp & Dohme LLCA Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038) | 2027-11-26 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing enlicitide in Hypercholesterolemia, from their registry updates:
Among Merck & Co., Inc’s 29 in Hypercholesterolemia:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to assess whether enlicitide is superior to ezetimibe or bempedoic acid or ezetimibe + bempedoic acid in reducing low-density lipoprotein cholesterol (LDL-C) in participants with hypercholesterolemia, and to evaluate its safety and tolerability. The primary study hypotheses are enlicitide is superior to ezetimibe, bempedoic acid, and ezetimibe + bempedoic acid on mean percent change from baseline in LDL-C at week 8.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive enlicitide 20mg, ezetimibe-matching placebo, and bempedoic acid-matching placebo once daily (QD) orally up to approximately 56 days.
Drug: Enlicitide · Other: Placebo for Ezetimibe · Other: Placebo for Bempedoic Acid
Participants receive ezetimibe 10mg, enlicitide-matching placebo, and bempedoic acid-matching placebo QD orally up to approximately 56 days.
Drug: Ezetimibe · Other: Placebo for Enlicitide · Other: Placebo for Bempedoic Acid
Participants receive bempedoic acid 180mg, ezetimibe-matching placebo, and enlicitide-matching placebo QD orally up to approximately 56 days.
Drug: Bempedoic Acid · Other: Placebo for Enlicitide · Other: Placebo for Ezetimibe
Participants receive ezetimibe 10 mg, bempedoic acid 180mg, enlicitide-matching placebo orally QD for approximately 56 days.
Drug: Ezetimibe · Drug: Bempedoic Acid · Other: Placebo for Enlicitide
Oral tablet
Also known as: MK-0616, Enlicitide Decanoate
Oral tablet
Oral capsule
enlicitide-matching placebo oral tablet
ezetimibe-matching placebo oral tablet
bempedoic acid-matching placebo oral capsule
Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Day 56
Blood samples were collected at baseline and after 56 days of treatment to assess mean percentage change in LDL-C. The mean percent change from baseline in LDL-C at Day-56 is reported.
Time frame: Baseline and Day 56
Mean Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 56
Blood samples were collected at baseline and on day 56 of treatment to assess mean percent change in ApoB. The mean percent change from baseline in ApoB at Day 56 is reported.
Time frame: Baseline and Day 56
Mean Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Day 56
Blood samples were collected at baseline and on day 56 of treatment to assess mean percent change in non-HDL-C. The mean percent change from baseline in non-HDL-C at 56 days is reported.
Time frame: Baseline and Day 56
Median Percent Change From Baseline in Lipoprotein(a) Levels (Lp[a])
Blood samples were collected at baseline and on day 56 of treatment to assess median percent change in Lp(a) levels. The median percent change from baseline at Day 56 is reported.
Time frame: Baseline and Day 56
Percentage of Participants Who at Day 56 Have an LDL-C <70 mg/dL and ≥50% Reduction From Baseline
Blood samples were collected at baseline and after 56 days of treatment to assess the percentage of participants who have an LDL-C \<70 mg/dL and ≥50% reduction from baseline at day 56. The percentage of participants who have LDL-C \<70 mg/dL and ≥50% reduction from baseline is reported.
Time frame: Baseline and Day 56
Percentage of Participants Who at Day 56 Have an LDL-C <55 mg/dL and ≥50% Reduction From Baseline
Blood samples were collected at baseline and after 56 days of treatment to assess the percentage of participants who have an LDL-C \<55 mg/dL and ≥50% reduction from baseline at day 56. The percentage of participants who have LDL-C \<55 mg/dL and ≥50% reduction from baseline is reported.
Time frame: Baseline and Day 56
Percentage of Participants With ≥1 Adverse Event (AE)
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an AE is reported.
Time frame: Up to approximately 147 days
Percentage of Participants Discontinuing From Study Intervention Due to AE
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study intervention due to an AE is reported.
Time frame: Up to approximately 91 days
| Milestone | Enlicitide | Bempedoic Acid | Ezetimibe | Ezetimibe + Bempedoic Acid |
|---|---|---|---|---|
| Started | 101 | 50 | 50 | 100 |
| Completed | 100 | 48 | 50 | 100 |
| Not completed | 1 | 2 | 0 | 0 |
| Withdrew: Participant moved | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 0 |
Blood samples were collected at baseline and after 56 days of treatment to assess mean percentage change in LDL-C. The mean percent change from baseline in LDL-C at Day-56 is reported.
| Percent Change | Enlicitide | Bempedoic Acid | Ezetimibe | Ezetimibe + Bempedoic Acid |
|---|---|---|---|---|
| Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Day 56 | -64.6 (-68.3 to -60.9) | -6.3 (-13.5 to 0.8) | -27.8 (-32.3 to -23.4) | -36.5 (-40.8 to -32.2) |
Blood samples were collected at baseline and on day 56 of treatment to assess mean percent change in ApoB. The mean percent change from baseline in ApoB at Day 56 is reported.
| Percent Change | Enlicitide | Bempedoic Acid | Ezetimibe | Ezetimibe + Bempedoic Acid |
|---|---|---|---|---|
| Mean Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 56 | -54.6 (-57.6 to -51.6) | -5.4 (-10.3 to -0.5) | -20.2 (-23.3 to -17.2) | -27.7 (-31.1 to -24.3) |
Blood samples were collected at baseline and on day 56 of treatment to assess mean percent change in non-HDL-C. The mean percent change from baseline in non-HDL-C at 56 days is reported.
| Percent Change | Enlicitide | Bempedoic Acid | Ezetimibe | Ezetimibe + Bempedoic Acid |
|---|---|---|---|---|
| Mean Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Day 56 | -58.0 (-61.3 to -54.7) | -5.2 (-11.5 to 1.1) | -25.1 (-28.7 to -21.6) | -31.8 (-35.8 to -27.9) |
Blood samples were collected at baseline and on day 56 of treatment to assess median percent change in Lp(a) levels. The median percent change from baseline at Day 56 is reported.
| Percent Change | Enlicitide | Bempedoic Acid | Ezetimibe | Ezetimibe + Bempedoic Acid |
|---|---|---|---|---|
| Median Percent Change From Baseline in Lipoprotein(a) Levels (Lp[a]) | -26.2 (-84.4 to 12.7) | 8.1 (-94.2 to 103.3) | 0.0 (-27.4 to 47.0) | 10.4 (-50.5 to 321.8) |
Blood samples were collected at baseline and after 56 days of treatment to assess the percentage of participants who have an LDL-C \<70 mg/dL and ≥50% reduction from baseline at day 56. The percentage of participants who have LDL-C \<70 mg/dL and ≥50% reduction from baseline is reported.
| Percentage of Participants | Enlicitide | Bempedoic Acid | Ezetimibe | Ezetimibe + Bempedoic Acid |
|---|---|---|---|---|
| Percentage of Participants Who at Day 56 Have an LDL-C <70 mg/dL and ≥50% Reduction From Baseline | 81.2 | 2.0 | 8.0 | 22.0 |
Blood samples were collected at baseline and after 56 days of treatment to assess the percentage of participants who have an LDL-C \<55 mg/dL and ≥50% reduction from baseline at day 56. The percentage of participants who have LDL-C \<55 mg/dL and ≥50% reduction from baseline is reported.
| Percentage of participants | Enlicitide | Bempedoic Acid | Ezetimibe | Ezetimibe + Bempedoic Acid |
|---|---|---|---|---|
| Percentage of Participants Who at Day 56 Have an LDL-C <55 mg/dL and ≥50% Reduction From Baseline | 78.2 | 2.0 | 8.0 | 20.0 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an AE is reported.
| Percentage of Participants | Enlicitide | Bempedoic Acid | Ezetimibe | Ezetimibe + Bempedoic Acid |
|---|---|---|---|---|
| Percentage of Participants With ≥1 Adverse Event (AE) | 39.6 | 38.0 | 36.0 | 45.0 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study intervention due to an AE is reported.
| Percentage of participants | Enlicitide | Bempedoic Acid | Ezetimibe | Ezetimibe + Bempedoic Acid |
|---|---|---|---|---|
| Percentage of Participants Discontinuing From Study Intervention Due to AE | 2.0 | 4.0 | 0.0 | 4.0 |
Collected over Death and adverse events up to 147 Days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Enlicitide 20 mg | 0/101 (0%) | 0/101 (0%) | 0/101 (0%) |
| Bempedoic Acid 180 mg | 0/50 (0%) | 4/50 (8%) | 3/50 (6%) |
| Ezetimibe 10 mg | 0/50 (0%) | 1/50 (2%) | 3/50 (6%) |
| Ezetimibe 10 mg and Bempedoic Acid 180 mg | 0/100 (0%) | 0/100 (0%) | 0/100 (0%) |
| Event | Enlicitide 20 mg | Bempedoic Acid 180 mg | Ezetimibe 10 mg | Ezetimibe 10 mg and Bempedoic Acid 180 mg |
|---|---|---|---|---|
| Myocardial infarctionCardiac disorders | 0/101 | 0/50 | 1/50 | 0/100 |
| Cholecystitis acuteHepatobiliary disorders | 0/101 | 1/50 | 0/50 | 0/100 |
| OverdoseInjury, poisoning and procedural complications | 0/101 | 1/50 | 0/50 | 0/100 |
| Transient ischaemic attackNervous system disorders | 0/101 | 1/50 | 0/50 | 0/100 |
| Mental disorderPsychiatric disorders | 0/101 | 1/50 | 0/50 | 0/100 |
| Event | Enlicitide 20 mg | Bempedoic Acid 180 mg | Ezetimibe 10 mg | Ezetimibe 10 mg and Bempedoic Acid 180 mg |
|---|---|---|---|---|
| Accidental overdoseInjury, poisoning and procedural complications | 0/101 | 3/50 | 3/50 | 0/100 |
| Age, Continuous(Years) | Enlicitide | Bempedoic Acid | Ezetimibe | Ezetimibe + Bempedoic Acid | Total |
|---|---|---|---|---|---|
| Mean | 64.3 ± 9.7 | 65.4 ± 10.2 | 65.4 ± 9.3 | 63.5 ± 10.9 | 64.4 ± 10.1 |
| Sex: Female, Male(Participants) | Enlicitide | Bempedoic Acid | Ezetimibe | Ezetimibe + Bempedoic Acid | Total |
|---|---|---|---|---|---|
| Female | 39 | 18 | 18 | 37 | 112 |
| Male | 62 | 32 | 32 | 63 | 189 |
| Ethnicity (NIH/OMB)(Participants) | Enlicitide | Bempedoic Acid | Ezetimibe | Ezetimibe + Bempedoic Acid | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 25 | 12 | 18 | 28 | 83 |
| Not Hispanic or Latino | 74 | 38 | 32 | 72 | 216 |
| Unknown or Not Reported | 2 | 0 | 0 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Enlicitide | Bempedoic Acid | Ezetimibe | Ezetimibe + Bempedoic Acid | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 26 | 16 | 14 | 24 | 80 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 8 | 5 | 3 | 5 | 21 |
| White | 66 | 29 | 33 | 70 | 198 |
| More than one race | 0 | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 1 |
| Renal Function measured by estimated Glomerular Filtration Rate (eGFR)(Participants) | Enlicitide | Bempedoic Acid | Ezetimibe | Ezetimibe + Bempedoic Acid | Total |
|---|---|---|---|---|---|
| ≥35 to <45 | 2 | 0 | 2 | 1 | 5 |
| ≥45 to <60 | 9 | 4 | 3 | 7 | 23 |
| ≥60 | 90 | 46 | 45 | 92 | 273 |
| Mean low-density lipoprotein cholesterol (LDL-C) at Baseline(mg/dL) | Enlicitide | Bempedoic Acid | Ezetimibe | Ezetimibe + Bempedoic Acid | Total |
|---|---|---|---|---|---|
| Mean | 89.9 ± 31.4 | 91.9 ± 24.4 | 93.2 ± 27.4 | 92.6 ± 33.4 | 91.6 ± 30.3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Jul 2024 to primary completion in Feb 2025, 7 months.
Results were first posted in Mar 2026, 1 year 1 month after primary completion.
Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 7 months is below that.
Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enlicitide